Conventional Longer MDR-TB Regimen (Injectable-containing)
Treatment for Multidrug-resistant tuberculosis without extensive drug resistance
Typical Dosage: Highly variable, individualized; includes an injectable drug for 6-8 months, and at least 4-5 second-line oral drugs
Effectiveness
60%
Safety Score
40%
Clinical Trials
100
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
Highly variable, individualized; includes an injectable drug for 6-8 months, and at least 4-5 second-line oral drugs
Time to Effect
3-4 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$6,000
Side Effect Mgmt:$5,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$150,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$24,194
Cost per Remission
$25,862
Conventional Longer MDR-TB Regimen (Injectable-containing) Outcomes
for Multidrug-resistant tuberculosis without extensive drug resistance
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+62%
Remission Rate
+58%
Common Side Effects
Hearing loss/vestibular toxicity (injectables)
+40%
Nephrotoxicity (injectables)
+25%
Gastrointestinal intolerance
+60%
Psychiatric disturbances (Cycloserine)
+15%
Hypothyroidism (Ethionamide, PAS)
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov